Conferences

Coverage from professional conferences on research relevant to pancreatic cancer.

Pancreatic

A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic agents have been evaluated in patients with pancreatic cancer. Gemcitabine (gem) and 5-FU are the
Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including
A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12 Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year This is a new approach to the management of pancreatic cancer, using paclitaxel (Taxol) and radiation therapy to improve
Simultaneous Gemcitabine/Cisplatin and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma using a Strict GEM/RT Time Schedule. A Phase I/II Study Presenter: T. Brunner Presenter's Affiliation: University Hospitals Erlangen, Erlangen, Germany Type of Session: Scientific Background Patients with locally advanced pancreatic cancer treated with induction chemoradiation (CRT) prior to surgery have a survival advantage as compared to patients treated with resection at diagnosis. Snady et al.
Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial Presenter: T. Dipetrillo Presenter's Affiliation: Brown University Type of Session: Scientific Background Locally advanced pancreatic cancer has Gemcitabine and paclitaxel are both radiation sensitizers The use of paclitaxel has demonstrated efficacy in RTOG 98-12 The feasibility of concurrent weekly paclitaxel and gemcitabine with
Initial Results Of Preoperative Gemcitabine (GEM)-Based Chemoradiation For Resectable Pancreatic Adenocarcinoma Presenter: Robert A WolffPresenter's Affiliation: UT MD Anderson Cancer Ctr, Houston, TXType of Session: ScientificBackground The recurrence rate in patients with adenocarcinoma of the pancreas following pancreaticoduodenectomy with curative intent is > 80% Preoperative Chemoradiotherapy increases the proportion of patients that undergo
Gemcitabine vs. GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: Interim results of GERCOR/GISCAD intergroup Phase III Presenter: C. LouvetPresenter's Affiliation: Hospital St. Antoine; Paris, FranceType of Session: ScientificBackground Gemcitabine 1g/m2 in a 30 min infusion remains the reference regimen for non-resectable pancreatic cancer. Oxaliplatin and Gemcitabine have different mechanisms of action and resistance The toxicity profiles of these two drugs is
A Phase III Trial comparing Gemcitabine plus Cisplatin vs. Gemcitabine alone in advanced pancreatic cancer Presenter: V. HeinemannPresenter's Affiliation: University of Munich; Munich, GermanyType of Session: ScientificBackground Pancreatic cancer has a very poor prognosis. Most patients are diagnosed in the metastatic stage. Median survival is 3-4 months with best supportive care. Single agent gemcitabine (Gem) has increased this MS to 5-6
Recent Clinical Advances in Pancreatic Cancer Conference Dates: September 28, 2005, 6:00pm Conference Location: Riva, 700 E. Grand Avenue/Navy Pier, Chicago, IL 60611 Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Who Should Attend: MDs and PAs Conference Agenda: Clinical Overview of Pancreatic Cancer Registration Information: Visit
Adjuvant Multimodality with Gemcitabine versus 5-Fluorouracil in Pancreatic Cancer: Status of U.S. Intergroup Trial Faculty Disclosure: William F. Regine, M.D. Nothing to Disclose Presenter: William F. Regine, M.D. Affiliation: University of Maryland Even with potentially curative resection, 5 year survival for pancreatic cancer patients is less than 20%. Approximately 25 years ago, the Gastrointestinal Study Group found a small survival advantage
Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG) Presenter: M.J. MoorePresenter's Affiliation: NCICType of Session: PlenaryBackground Advanced and metastatic pancreatic cancer has an extremely poor prognosis, with median survival times between 4-6 months. Multiple attempts at combination chemotherapy have shown no efficacy Attempts at targeted agents have also been negative trials Targeting
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma. Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after chemotherapy and radiation (around 9 months). GITSG trials from the 1980s showed a benefit to adding
Gemcitabine and Erlotinib in Pancreatic Cancer Presenter: Malcolm Moore, MDPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer-related deaths. In 2005, there will be an estimated 35,400 new cases and 35,000 deaths in the United States and Canada. The 5-year survival is dismal, hovering
Pancreatic Cancer: Progress on the Horizon Presented by: Shannon Holloway, MHS , PA -C, New York Presbyterian Weill Cornell Medical Center Pancreatic cancer accounts for 30,500 new cases annually, with a dismal 5-year survival rate of 15% when respectable, down to 1.8% when distant metastases are present. Approximately 80-95% of cases are unresectable at diagnosis, leading to the poor
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma Presenter: William F. ReginePresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Adenocarcinoma of the pancreas, even when resectable, has a poor prognosis. Failures occur both locoregionally and systemically. Adjuvant treatment of resected pancreas adenocarcinoma is
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma Presenter: Abrams, R et al.Presenter's Affiliation: University of Maryland School of MedicineType of Session: ScientificBackground Pancreatic cancer is a very difficult cancer to treat and cure A previously published phase II trial of locally advanced and/or metastatic pancreatic cancer demonstrated improved outcomes with gemcitabine
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma Intra-arterial vs. Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial Locally advanced squamous cell head and neck cancer is often treated with a combination of cisplatin chemotherapy and radiation therapy. The dose of cisplatin is limited by the side effects it causes. By giving
A Double-Blind, Placebo Controlled, Randomized Phase III trial of Gemcitabine (G) plus Bevacizumab (B) Versus Gemcitabine Plus Placebo (P) in Patients (pts) with Advanced Pancreatic Cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB) Presenter: H. L. KindlerPresenter's Affiliation: University of Chicago Medical CenterType of Session: ScientificBackground Advanced pancreatic cancer continues to have an extremely poor prognosis. Gemcitabine is the cornerstone of treatment and objective response rates of 5-10% are seen when gemcitibine is used alone. Treatment with
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Scientific Session: Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer There is no consensus on standard therapy for locally advanced pancreatic
Post-resectional CA 19-9 Values >90 are Associated With Significantly Worse Survival in Patients With Pancreatic Carcinoma Treated With Adjuvant Therapy on RTOG 9704 - Implications for Current and Future Trials Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Radiation Therapy Oncology GroupType of Session: ScientificBackground The CONKO-001 phase III trial (Oettle H, et al. JAMA. 2007;297(3):267-77) recently reported that adjuvant Gemcitabine without radiation resulted in improved disease free survival
Characterization of Pancreatic Tumor Motion Using 4D MRI: Surrogates for Tumor Position Should be Used With Caution Presenter: Mary Feng, MDPresenter's Affiliation: University of Michigan Medical CenterType of Session: PlenaryBackground Pancreatic cancer is associated with poor outcomes and limited long-term survival, and there are numerous challenges that treating physicians encounter. Less than 20% of patients are operable at the time of
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Presenter: C.H. Crane substituting for F. MornexPresenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon Pierre Benite, FranceType of Session: ScientificBackground Pancreatic cancer is the fourth most common malignancy in the United States, and the annual incidence rate is almost identical to the mortality rate. In 2007, over 37,000
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Presenter: Picozzi R.A.Presenter's Affiliation: Virginia Mason Medical Center, Seattle WashingtonType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented (Jemal, CA Cancer J Clin, 2007).
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) Presenter: Neumann J.P.Presenter's Affiliation: Charite School of Medicine, Berlin, GermanyType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States, and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented . Surgery is the only curative
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Surgery is considered the only curative therapy for pancreatic cancer. However, 50-80% of patients will develop recurrence after surgery. For this reason, patients also receive adjuvant (meaning
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) This study has previously reported (Oettle H., et al. JAMA 2007) that the use of post-operative gemcitabine in patients with pancreatic cancer
A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 Prior studies of gemcitabine with radiation therapy in pancreatic cancer have concluded that the drug adds toxicity, with little, if any benefit. But, gemcitabine if known
Postoperative Adjuvant Gemcitabine Plus Oxaliplatin (GemOx)Chemotherapy in Patients with Pancreatic Adenocarcinoma: Final Results of a Single Arm Multicenter Phase II Study Presenter: Francoise Mornex Presenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon, France Type of Session: Scientific Background Pancreas cancer treated with surgery alone has produced disappointing results including high rates of positive margins and rapid development of distant metastases At the time of initiation of this study,
Comparison of Proton and Photon Radiation Treatment Plans for the Adjuvant Treatment of Pancreatic Cancer Including Comprehensive Nodal Radiation Presenter: Mark Ingram Presenter's Affiliation: University of Pennsylvania Type of Session: Poster Background Pancreatic cancer is the fourth leading cause of death and most patients present with unresectable disease. The five year survival is poor even in patients who can be resected (5 year survival ~10%) and is even worse in patients who
Use of endoscopic ultrasonography in screening patients at high-risk for pancreatic cancer Presenter: J. Poley, University Medical Center, Rotterdam, Netherlands Background Screening of the general population for certain malignancies, including breast cancer, prostate cancer, colon cancer, and cervix cancer has become standard of care within the United States and in many countries abroad. The feasibility and cost-effectiveness of
First Report of Real-time Tumor Tracking in the Treatment of Pancreatic Cancer using the Calypso System Presenter: James M. Metz, MDPresenter's Affiliation: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PAType of Session: ScientificBackground In the United States, surgery followed by combined modality therapy with chemotherapy and radiation therapy remains the standard of care for the approximately 10-20% of patients
Five-year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Postchemoradiation (CRT) 5-FU vs. Gemcitabine (G) For Resected Pancreatic Adenocarcinoma: Implications for Future International Trial Design Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Baltimore, MDType of Session: ScientificBackground Due to the often advanced stage of presentation among patients with pancreatic adenocarcinoma, only 15-20% with head of the pancreas lesions and fewer with body and tail lesions are
Understanding Pancreatic Cancer: A Free Educational Lecture Dates: October 15, 2011 Location: Cancer Support Community of Philadelphia, The Suzanne Morgan Center at Ridgeland, 4100 Chamounix Dr., Phila. PA 19131 Sponsoring Group: Pancreatic Cancer Action Network and the Cancer Support Community of Philadelphia Web Page URL: http://www.pancan.org Topics Covered: Diet and nutrition issues,
Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% of patients who present with resectable disease experience 5-year survivals of only 10-25%.